Fate Therapeutics (FATE) Tops Q2 EPS by 2c

August 8, 2016 5:20 PM EDT
Get Alerts FATE Hot Sheet
Trade FATE Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.29), $0.02 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $1.03 million versus the consensus estimate of $1.02 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment